Latest metastatic colorectal cancer Stories
BONN, Germany, September 29, 2014 /PRNewswire/ -- Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.
Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found.
- A trick or prank.